Demonstrated results in percutaneous coronary intervention
28.8%
reduction in contrast agent with Dynamic Coronary Roadmap1
Clinical Study: Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial.
85%
believe TSM control of HEMO visualizations improves workflow.2
A usability study revealed that 85% of users believe the Azurion TSM control of HEMO visualizations and measurements improves workflow.2 To evaluate benefits of the multi-user capabilities of the new system design and user satisfaction, its novel design was tested by 33 participants.
$896
saved per patient with Philips iFR compared to FFR.3
An analysis to assess a cost-minimization of iFR-guided compared with FFR-guided revascularization demonstrated a cost saving per patient of $681 (95% CI: $641 - $723) in the Nordic setting and $1024 (95% CI: $934 - $1114) in the US, when using iFR-guided revascularization.3
Dynamic Coronary Roadmap is a great asset to add to the interventional toolkit. It is an easy-to-use tool which reduces the contrast exposure to patients. It is very useful in patients with low GFR or patients with branch vessel disease. I use it very frequently to assist in decreasing contrast use.
Improving patient care at Robert Bosch Hospital
See how Robert Bosch Hospital’s cardiac center implemented a multimodality imaging system, Philips Azurion with IntraSight, and enabled complex imaging.